GUAVA PERSONAL CELL ANALYSIS-96 SYSTEM: CANCER

该子项目是利用由NIH/NCRR资助的共享仪器赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。列出的机构是用于资助的，不一定是研究者的机构。描述（由申请人提供）：本申请要求支持Guava EasyCyte，该系统允许在96孔板中分析样本的细胞计数和活力、蛋白表达、Multicaspase、TUNEL和细胞周期。虽然大多数这些测定可以在单个实验室中以小规模进行，但它们耗时且昂贵，并且结果通常是可变的且取决于用户。有机会集中这些研究，并提供最先进的设备，用于各种细胞反应的高通量测定，将最大限度地减少成本和时间，并最大限度地提高产量。目前，福克斯蔡斯癌症中心没有具有类似能力的仪器，也没有资金用于这种仪器。虽然代表Guava EasyCyte预计用户的11个NIH资助实验室的具体项目各不相同，但它们都有一个共同的目标，即确定小分子，药物或基因表达改变对癌细胞生物学的影响，特别是细胞周期和细胞凋亡的调控途径。所要求的仪器将被安置，管理和维护在福克斯大通癌症中心的转化研究核心设施，这是我们新的转化计划的一部分，正在迅速扩大。该基金的主要目标是支持基础科学家和临床研究人员之间互动产生的新的转化研究计划，并协助开发癌症的新疗法。鉴于我们实验室的规模相对较小（平均= 4.5），除非我们的人手有限，而中央设施又能增加人手，否则大部分的研究都是不可行的。该仪器的获得将提供第一个关键步骤，以提供高通量，集中支持，以承担本提案中列出的NIH研究人员的临床相关项目，以及随着更多研究人员意识到该仪器的出色功能，肯定会出现的许多新举措。

This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): This application requests support for a Guava EasyCyte, a system that allows samples to be assayed for cell count and viability, protein expression, Multicaspase, TUNEL and the cell cycle in a 96-well format. Although most of these assays can be performed on a small scale in individual laboratories, they are time-consuming and expensive, and results are often variable and user-dependent. The opportunity to centralize these studies and provide state-of-the-art equipment for high-throughput assays of a variety of cell responses will minimize cost and time, and maximize output. At present there is no instrument with similar capabilities at Fox Chase Cancer Center, nor is there funding available for such instrumentation. While the specific projects of the 11 NIH funded laboratories that represent the projected users of the Guava EasyCyte vary, they share the common goal of determining the effects of small molecules, pharmaceuticals or the alteration of gene expression on cancer cell biology, particularly the regulatory pathways of the cell cycle and apoptosis. The instrument requested will be housed, managed and maintained in the Translational Research Core Facility of Fox Chase Cancer Center, which is undergoing rapid expansion as part of our new Translational Initiative. The primary goal of the Facility is to support new translational research initiatives that arise from interactions among basic scientists and clinical investigators and to assist in the development of novel therapies for cancer. Given the relatively small size of our laboratories (avg.=4.5), most of these studies would not be feasible unless our limited manpower was augmented by this centralized facility. Acquisition of this instrument will provide a first critical step toward providing the high-throughput, centralized support necessary to undertake the clinically-relevant projects of the NIH investigators listed in this proposal, as well as the many new initiatives that are sure to arise as additional investigators become aware of the outstanding capabilities of this instrument.